Customize Consent Preferences

We use cookies to help you navigate efficiently and perform certain functions. You will find detailed information about all cookies under each consent category below.

The cookies that are categorized as "Necessary" are stored on your browser as they are essential for enabling the basic functionalities of the site. ... 

Always Active

Necessary cookies are required to enable the basic features of this site, such as providing secure log-in or adjusting your consent preferences. These cookies do not store any personally identifiable data.

No cookies to display.

Functional cookies help perform certain functionalities like sharing the content of the website on social media platforms, collecting feedback, and other third-party features.

No cookies to display.

Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics such as the number of visitors, bounce rate, traffic source, etc.

No cookies to display.

Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.

No cookies to display.

Advertisement cookies are used to provide visitors with customized advertisements based on the pages you visited previously and to analyze the effectiveness of the ad campaigns.

No cookies to display.

Effects of supplementary protection mechanisms for pharmaceutical products

Fecha de publicación: 15 junio 2018 | Idioma del informe EN

To stimulate the development of new medicines, various forms of ‘supplementary protections’ exist that give companies extended monopoly rights. This includes: Supplementary Protection Certificates (SPCs), which prolong the patent protection for medicinal products by up to five years; paediatric extensions to SPCs; regulatory protection in the form of data and market exclusivity; as well as regulatory protection in the form of the orphan drug regulation which intends to spur development for drugs to treat rare diseases.

Technopolis Group has prepared a report on the impacts of these intertwined mechanisms on pharmaceutical innovation and healthcare costs. This assessment is based on a review of available secondary data sources and literature; an interview programme with experts; a legal analysis on the four instruments; as well as seven case studies that illustrate the combined use of the instruments in real-life settings and the extent to which it was possible to manage patent life beyond the 20-year protection with the corresponding impacts. The study was prepared in collaboration with experts from the University of Liverpool and the University of Amsterdam. While the report has a focus on the Dutch market and was presented to the Dutch Parliament, the major discussion threads are applicable throughout Europe, given the highly international character of SPC/supplementary protection mechanisms. The study, while focused on the IP side, also ties into other cross-cutting analyses where Technopolis has been, in consortia, recently tasked by the European Commission to review the paediatric regulation and the orphan drug regulation